Progesterone: Review of safety for clinical studies

被引:47
作者
Goletiani, Nathalie V.
Keith, Diana R.
Gorsky, Sara J.
机构
[1] McLean Hosp, Alcohol & Drug Abuse Res Ctr, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Cambridge, MA 02138 USA
关键词
progesterone; micronized progesterone; synthetic progesterone;
D O I
10.1037/1064-1297.15.5.427
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Progesterone is a steroid hormone that is important for reproductive function. Progesterone is used in a number of clinical applications and has been investigated as a possible novel approach for treatment of stimulant drug abuse. Extensive clinical studies have been conducted to examine the subjective and physiological effects of exogenous progesterone administration and to evaluate its side effects. This review summarizes the safety and side effects of acute and chronic administration of 3 progesterone formulations (synthetic, natural, and micronized natural), several routes of administration (oral, intramuscular, intravenous, intravaginal, intranasal, transdermal, and rectal), and dosing regimens. Synthetic progestins marketed as Provera, PremPro, and Cycrin are widely used but may produce a number of significant side effects, such as fatigue, fluid retention, lipid level alterations, dysphoria, hypercoagulant states, and increased androgenicity. Natural progesterones are reported to have milder adverse effects, depending on the route of administration. Micronized natural progesterone is available for oral administration, has better bioavailability and fewer side effects than natural progesterone, and is convenient to administer. Therefore, micronized natural progesterone appears to be a safe and effective alternative to synthetic and natural progesterone formulations for variety of clinical and research applications.
引用
收藏
页码:427 / 444
页数:18
相关论文
共 146 条
[1]  
Abrams LS, 2002, FERTIL STERIL, V77, pS3
[2]   Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman [J].
Abu, J ;
Brown, L ;
Ireland, D .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (03) :1445-1447
[3]   A 5-YEAR CLINICAL-EVALUATION OF NORPLANT(R) CONTRACEPTIVE SUBDERMAL IMPLANTS IN BANGLADESHI ACCEPTORS [J].
AKHTER, H ;
DUNSON, TR ;
AMATYA, RN ;
BEGUM, K ;
CHOWDHURY, T ;
DIGHE, N ;
KRUEGER, SL ;
RAHMAN, S .
CONTRACEPTION, 1993, 47 (06) :569-582
[4]   Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women [J].
Aktun, H ;
Moroy, P ;
Cakmak, P ;
Yalcin, HR ;
Mollamahmutoglu, L ;
Danisman, N .
CONTRACEPTION, 2005, 72 (01) :24-27
[5]   Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone [J].
Andréen, L ;
Sundström-Poromaa, I ;
Bixo, M ;
Andersson, A ;
Nyberg, S ;
Bäckström, T .
PSYCHONEUROENDOCRINOLOGY, 2005, 30 (02) :212-224
[6]  
[Anonymous], 2006, PHYS DESK REFERENCE, V61st ed.
[7]  
Apgar BS, 2000, AM FAM PHYSICIAN, V62, P1839
[8]   INITIAL AND STEADY-STATE PHARMACOKINETICS OF A VAGINALLY ADMINISTERED FORMULATION OF PROGESTERONE [J].
ARCHER, DF ;
FAHY, GE ;
VINIEGRASIBAL, A ;
ANDERSON, FD ;
SNIPES, W ;
FOLDESY, RG .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (02) :471-478
[9]   Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial [J].
Audet, MC ;
Moreau, M ;
Koltun, WD ;
Waldbaum, AS ;
Shangold, G ;
Fisher, AC ;
Creasy, GW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2347-2354
[10]   Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats [J].
Bäckström, T ;
Wahlström, G ;
Wahlström, K ;
Zhu, D ;
Wang, MD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 512 (01) :15-21